Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

15.25 2.83

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.77

Max

15.25

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.4M -14M
EPS	-0.15
Angestellte	37
EBITDA	312K -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+107.49% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-199M 1.1B
Vorheriger Eröffnungskurs	12.42
Vorheriger Schlusskurs	15.25

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Juli 2026, 23:52 UTC

U.S. job growth disappoints, reducing Fed rate hike expectations, while global equities rise amid easing U.S.-Iran tensions and stable oil prices.

3. Juli 2026, 23:52 UTC

European equity indices rise as weaker U.S. job growth dampens Fed rate hike expectations, while ECB signals caution amid mixed economic indicators.

3. Juli 2026, 23:52 UTC

Global equity markets rise as U.S. job growth disappoints and European economic indicators show mixed signals, prompting cautious outlook on interest rate hikes.

3. Juli 2026, 23:52 UTC

Asia equity markets rise as U.S. jobs data eases Fed rate hike concerns, boosting sentiment and commodities like gold and oil.

3. Juli 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Awaits Insights Amid World Cup Spending Boost and Economic Uncertainty.

3. Juli 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Eyes Potential Shifts Amid Service Sector Growth and Global Pressures.

3. Juli 2026, 23:41 UTC

Spain's Consumer Confidence Index Holds Steady at 77.7 Amid Geopolitical Tensions and Inflation Concerns

3. Juli 2026, 23:41 UTC

Correlated Moves

Macro News

Bitcoin is gaining ground amid improved sentiment following a weaker U.S. jobs report, which has eased expectations for Federal Reserve interest rate hikes.

3. Juli 2026, 23:31 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected Amid Cautious Optimism Over Global Price Trends.

3. Juli 2026, 23:31 UTC

Mexico's Inflation Rate MoM Release on July 9, 2026: Market Anticipates Impact from U.S. Monetary Policy Adjustments and Global Economic Pressures.

3. Juli 2026, 23:22 UTC

U.S. Balance of Trade Report Set for July 7, Anticipating $78.8 Billion Deficit Amid Labor Market Concerns and Global Economic Volatility

3. Juli 2026, 23:22 UTC

U.S. Imports Data Release on July 7, 2026: Analysts Anticipate Cautious Optimism Amid Tariff Influences and Supply Chain Concerns

3. Juli 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Show Continued Growth Amid Geopolitical Tensions and Trade Policy Changes

3. Juli 2026, 23:22 UTC

Canada's Trade Balance Expected to Show C$2.4 Billion Surplus Amid Optimism in Export Performance and Market Uncertainty Over U.S. Trade Relations

3. Juli 2026, 23:21 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a broader market decline linked to disappointing U.S. job growth data.

3. Juli 2026, 23:21 UTC

Correlated Moves

The S&P 500 Index is trading lower in after-market hours, reflecting minimal movement since Friday's close amid weaker U.S. jobs data.

3. Juli 2026, 23:21 UTC

Nasdaq 100 Index declines slightly in after-market trading, remaining flat overall. Recent U.S. nonfarm payrolls report eases interest rate hike concerns.

3. Juli 2026, 23:21 UTC

Correlated Moves

The Dow Jones Index is trading lower in after-market hours, reflecting a weak performance since Friday's close amid disappointing U.S. nonfarm payrolls data.

3. Juli 2026, 23:21 UTC

The FTSE 100 Index is trading lower in after-market hours, with no specific news identified to explain the decline.

3. Juli 2026, 23:11 UTC

Brazil's Retail Sales MoM report on July 8, 2026, signals cautious market sentiment amid recent declines and economic uncertainty.

3. Juli 2026, 23:11 UTC

Correlated Moves

XRP is trading higher, buoyed by positive sentiment in the digital currency market and softer U.S. nonfarm payrolls data impacting interest rate expectations.

3. Juli 2026, 23:11 UTC

Correlated Moves

Macro News

Ethereum is trading higher since Thursday, supported by increased interest in Pepeto and a correlated rise in Bitcoin. Earlier, it pulled back from a session high.

3. Juli 2026, 23:01 UTC

Declining 30-Year Mortgage Rates Signal Potential Boost in U.S. Housing Market Confidence and Activity

3. Juli 2026, 23:01 UTC

Terra is trading higher during Friday's session, maintaining upward momentum since Thursday. No specific news has been identified to explain this price movement.

3. Juli 2026, 23:01 UTC

Cardano is trading higher today, continuing a notable increase since Thursday's close. The asset remains above its 20-day moving average.

3. Juli 2026, 22:51 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Global Economic Influences on July 6, 2026.

3. Juli 2026, 22:51 UTC

Japan's Current Account data release on July 7, 2026, forecasts a JPY 4.1 trillion surplus amid cautious market sentiment and potential currency volatility concerns.

3. Juli 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, with no specific news identified. Recent U.S. jobs data may be influencing market sentiment.

3. Juli 2026, 22:31 UTC

UK Housing Market Faces Negative Outlook as RICS House Price Balance Forecasts -0.32% Amid Economic Pressures and Inflation Concerns

3. Juli 2026, 22:11 UTC

Japan's Household Spending Data Set for Release Amidst Declining Consumer Confidence and Currency Market Volatility

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

107.49% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 107.49%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.